Anika Therapeutics (ANIK) Profit After Tax (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Profit After Tax data on file, last reported at -$5.4 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 10.96% year-over-year to -$5.4 million in Q1 2026; TTM through Mar 2026 was -$10.8 million, a 70.52% increase from a year earlier, with the FY2025 full-year figure at -$10.9 million, down 23.24% from the prior year.
• Profit After Tax for Q1 2026 stood at -$5.4 million, down from $900000.0 in the prior quarter.
• Over the last five years, Profit After Tax for ANIK reached as high as $16.3 million in Q4 2023 and fell as low as -$29.2 million in Q3 2024.
• Historically, Profit After Tax has averaged -$4.1 million across 5 years, with a median of -$3.9 million in 2022.
• Across the five-year window, Profit After Tax soared 524.21% in 2023 and tumbled 4411.36% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$3.9 million in 2022, then surged by 524.21% to $16.3 million in 2023, then sank by 115.21% to -$2.5 million in 2024, then jumped by 136.2% to $900000.0 in 2025, then tumbled by 700.78% to -$5.4 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$5.4 million in Q1 2026, $900000.0 in Q4 2025, and -$2.3 million in Q3 2025.